Buccal Drug Delivery Systems Market - By Product (Tablet, Film, Spray, Gel, Patch), Application (Pain Management, Hormone Replacement, Cardiovascular, Respiratory & Neurological Disorder), System (Matrix, Reservoir), End-use – Global Forecast 2024 – 2032

Buccal Drug Delivery Systems Market Size

Buccal Drug Delivery Systems Market size was valued at around USD 3.9 billion in 2023 and is estimated to grow at 8.6% CAGR from 2024 to 2032. Buccal drug delivery systems involve administering a drug through the buccal mucosa (the lining of the cheek) to achieve systemic or local effects. This method utilizes the mucous membrane inside the mouth to absorb the drug directly into the bloodstream, bypassing the gastrointestinal tract and first-pass metabolism in the liver.
 

The market is gaining traction due to its ability to enhance drug bioavailability, improve patient compliance, and accommodate ongoing advancements in pharmaceutical drug delivery technologies. The rising prevalence of chronic diseases and a supportive regulatory landscape further bolster its market growth. A key driver for buccal drug delivery systems is the enhanced bioavailability achieved through this route. Buccal administration increases drug bioavailability by bypassing the gastrointestinal tract and hepatic first-pass metabolism, allowing more drug to enter systemic circulation. Additionally, it is non-invasive and easy to administer, improving compliance among those who have difficulty swallowing pills, such as pediatric and geriatric patients.
 

Moreover, the increasing incidence of chronic diseases, such as cardiovascular diseases and diabetes, which require long-term medication, is also driving the demand for alternative drug delivery systems like buccal routes that offer sustained and controlled drug release.
 

Buccal Drug Delivery Systems Market Trends

• Regulatory agencies are increasingly endorsing buccal drug delivery products, recognizing their proven efficacy and safety. This trend is prompting pharmaceutical companies to invest more in this area and expand their product development efforts.
   
• Furthermore, there is an increasing emphasis on precision medicine within the market. Companies are focusing on developing buccal delivery solutions that can be customized to address the specific needs of individual patients. This approach not only enhances the therapeutic efficacy of treatments but also aligns with the broader healthcare trend of tailoring medical interventions to achieve optimal patient outcomes.
   

Buccal Drug Delivery Systems Market Analysis

Based on product type, the market is segmented into buccal tablets, buccal films, buccal gels, buccal sprays, and buccal patches. The buccal films segment dominated the market with the largest revenue of USD 1.6 billion in 2023.
 

• The growing demand for non-invasive and patient-centric drug delivery solutions is a key driver in the market. Buccal films, which adhere to the inner mucosa of the cheek, present a convenient and less invasive alternative to conventional oral or injectable treatments. This method not only enhances patient compliance but also ensures a controlled, sustained release of medication, offering significant advantages for the management of chronic conditions.
   
• Additionally, innovations such as the development of mucoadhesive polymers, bioenhancers, and novel film technologies are enhancing the effectiveness and stability of buccal films. These advancements enable the creation of more efficient drug delivery systems that can improve the bioavailability of drugs and ensure a more consistent therapeutic effect.

Based on application, the buccal drug delivery systems market is segmented into pain management, hormone replacement, cardiovascular diseases, neurological disorders, respiratory disorders, addiction treatment, and mental health disorders. The pain management segment dominated the market and was valued at USD 1.4 billion in 2023.
 

• The rising prevalence of chronic pain conditions drives the market for buccal drug delivery systems. Conditions such as arthritis, neuropathic pain, and fibromyalgia require ongoing pain management strategies, and buccal systems provide a convenient method for delivering pain relief medications on a regular basis.
   
• Additionally, increased investment in research and development by pharmaceutical companies is fostering innovation in buccal pain management solutions. Companies are exploring new formulations and delivery methods to improve the efficacy of buccal systems for pain relief, which supports the growth of the market.
   

Based on system type, the buccal drug delivery systems market is bifurcated into matrix systems and reservoir systems. The matrix systems segment held the largest revenue of USD 2.5 billion in 2023.
 

• Matrix buccal systems utilize a matrix of polymers and excipients to encapsulate the drug, enabling a steady and prolonged release of medication. This controlled-release mechanism ensures a consistent therapeutic effect over an extended period, which is particularly beneficial for managing chronic conditions and providing long-lasting pain relief or medication adherence.
   
• Additionally, the rising demand for effective non-invasive drug delivery solutions is a major market driver for matrix buccal systems. These systems provide a patient-friendly alternative to conventional oral or injectable therapies, offering a simple and minimally invasive administration method. Their ease of use and convenience has positioned the matrix buccal systems as an attractive option for patients seeking both effective and user-friendly treatment alternatives.
   

Based on end-use, the buccal drug delivery systems market is segmented into hospitals, homecare settings, specialty clinics, ambulatory surgery centers, and other end-users. The hospitals segment held the largest revenue of USD 1.7 billion in 2023.
 

• The growing emphasis on patient compliance and streamlined drug administration in hospital settings is a significant driver for the adoption of buccal drug delivery systems. These systems provide a simple, non-invasive alternative to complex intravenous or intramuscular injections, minimizing procedural complexity and reducing the risk of administration errors. This straightforward approach not only boosts operational efficiency for healthcare providers but also enhances patient comfort and adherence to prescribed treatment regimens.
   
• Additionally, increased investment in the development of advanced pharmaceutical products for hospital use is fueling the growth of the market. This focus on innovation aims to meet the evolving needs of hospital-based patient care and treatment efficacy.

The North America buccal drug delivery systems market is forecasted to reach USD 3.2 billion by 2032, propelled by technological advancements, heightened public awareness, and the rising prevalence of chronic diseases. The U.S. dominated the North America market with the largest revenue of USD 1.4 billion in 2023.
 

• The rising incidence of chronic conditions like diabetes and cardiovascular diseases in North America is driving the demand for effective, long-term medication solutions. Buccal drug delivery systems provide a reliable method for sustained drug release, meeting the needs of patients managing these chronic diseases.
   
• Additionally, there is a strong market demand for innovative drug delivery solutions that offer convenience and minimize patient discomfort. Buccal drug delivery systems, with their non-invasive and user-friendly design, cater to this demand by offering an effective alternative to traditional oral and injectable therapies.
   

The buccal drug delivery systems market in UK is expected to experience significant and promising growth from 2024 to 2032.
 

• The UK’s healthcare system is increasingly focused on patient-centered approaches, and buccal drug delivery systems offer a non-invasive, convenient method for medication administration that aligns with this focus, enhancing patient comfort and compliance.
   
• Additionally, the UK’s rigorous regulatory environment, governed by the Medicines and Healthcare products Regulatory Agency (MHRA), ensures that only high-quality, effective buccal drug delivery products are approved for use. This robust regulatory framework supports the development and introduction of innovative buccal therapies.
   

Japan buccal drug delivery systems market is anticipated to witness lucrative growth between 2024 – 2032.
 

• With one of the highest proportions of elderly citizens in the world, Japan faces a growing prevalence of age-related conditions such as cardiovascular diseases, diabetes, and chronic pain. Buccal drug delivery systems are particularly suited for managing these chronic conditions, offering a sustained and controlled release of medications that are ideal for long-term disease management.
   
• Additionally, Japan is known for its advanced research and development capabilities in the pharmaceutical sector. The country's commitment to cutting-edge medical technology is fostering the development of sophisticated buccal drug delivery systems that utilize the latest advancements in polymer science, drug formulation, and delivery mechanisms.
   

The buccal drug delivery systems market in Saudi Arabia is expected to experience significant and promising growth from 2024 to 2032.
 

• Saudi Arabia’s Vision 2030 initiative emphasizes the advancement of healthcare infrastructure and the integration of innovative medical technologies. Buccal drug delivery systems fit seamlessly into this vision by offering effective and efficient drug administration solutions that support the country’s goals of modernizing and optimizing healthcare services.
   
• Additionally, the growth of the private healthcare sector in Saudi Arabia is creating opportunities for the adoption of advanced medical technologies. Buccal drug delivery systems are well-suited for this expanding market, offering convenient and effective treatment options for patients in private hospitals and clinics.
   

Buccal Drug Delivery Systems Market Share

The buccal drug delivery systems sector is competitive in nature, with a mix of major global and smaller to medium-sized companies competing for market share. A pivotal aspect of market strategy involves the continual introduction of innovations such as advanced mucoadhesive buccal systems, buccal films and tablets with advanced formulations, nano-enhanced buccal delivery systems, and bio-responsive buccal drug delivery systems. Notably, prominent industry players command considerable influence in this dynamic landscape, often driving forward advancements through substantial investments in research and development. Additionally, strategic alliances, acquisitions, and mergers are instrumental in fortifying market positions and expanding global footprint amidst evolving regulatory landscapes.
 

Buccal Drug Delivery Systems Market Companies

Some of the eminent market participants operating in the buccal drug delivery systems industry include:

• AbbVie Inc.
• Amgen Inc.
• Collegium Pharmaceutical, Inc.
• Endo International plc
• Galderma SA
• Indivior plc
• Johnson & Johnson Services, Inc.
• Kyowa Kirin Co., Ltd.
• Mallinckrodt plc
• Neurelis, Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi
• Takeda Pharmaceuticals Company Limited
• Teva Pharmaceutical Industries Ltd.
   

Buccal Drug Delivery Systems Industry News:

• In February 2024, Takeda Pharmaceuticals Company Limited announced that the U.S. Food and Drug Administration (FDA) had granted approval for EOHILIA (budesonide oral suspension), marking it as the first and only FDA-approved oral treatment for patients aged 11 and older with eosinophilic esophagitis (EoE). Packaged in 2 mg/10 mL single-dose stick packs, this innovative therapy established Takeda Pharmaceuticals Company Limited’s leadership in the EoE market and presents new growth opportunities for the company’s oral drug delivery portfolio.
• In March 2022, Collegium Pharmaceutical, Inc. announced the completion of its acquisition of BioDelivery Sciences International Inc. This strategic move diversified and expanded Collegium's revenue streams by incorporating BELBUCA as a complementary growth driver to its existing pain portfolio. Additionally, the acquisition brought in SYMPROIC as a contributing product and introduced a new product launch opportunity with ELYXYB.
   

The buccal drug delivery systems market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Buccal tablets
• Buccal films
• Buccal gels
• Buccal sprays
• Buccal patches

Market, By Application

• Pain management
• Hormone replacement
• Cardiovascular diseases
• Neurological disorders
• Respiratory disorders
• Addiction treatment
• Mental health disorders

Market, By System Type

• Matrix systems
• Reservoir systems

Market, By End-use

• Hospitals
• Homecare settings
• Specialty clinics
• Ambulatory surgical centers
• Other end-users

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America 
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa